Pembroke Thomas Peter Ignatius, John Gareth, Puyk Berry, Howkins Keith, Clarke Ruth, Yousuf Fidan, Czajkowski Marek, Godkin Andrew, Salmon Jane, Yeoman Andrew
Department of Gastroenterology and Hepatology, University Hospital of Wales, Cardiff CF14 4XN, United Kingdom.
Division of Infection and Immunity, Cardiff University, Cardiff CF14 4XW, United Kingdom.
World J Hepatol. 2023 Jan 27;15(1):89-106. doi: 10.4254/wjh.v15.i1.89.
Liver disease incidence and hence demand on hepatology services is increasing.
To describe trends in incidence and natural history of liver diseases in Wales to inform effective provision of hepatology services.
The registry is populated by International Classification of Diseases-10 (ICD-10) code diagnoses for residents derived from mortality data and inpatient/day case activity between 1999-2019. Pseudo-anonymised linkage of: (1) Causative diagnoses; (2) Cirrhosis; (3) Portal hypertension; (4) Decompensation; and (5) Liver cancer diagnoses enabled tracking liver disease progression.
The population of Wales in 2019 was 3.1 million. Between 1999 and 2019 73054 individuals were diagnosed with a hepatic disorder, including 18633 diagnosed with cirrhosis, 10965 with liver decompensation and 2316 with hepatocellular carcinoma (HCC). Over 21 years the incidence of liver diseases increased 3.6 fold, predominantly driven by a 10 fold increase in non-alcoholic fatty liver disease (NAFLD); the leading cause of liver disease from 2014. The incidence of cirrhosis, decompensation, HCC, and all-cause mortality tripled. Liver-related mortality doubled. Alcohol-related liver disease (ArLD), autoimmune liver disease and congestive hepatopathy were associated with the highest rates of decompensation and all-cause mortality.
A 10 fold increase in NAFLD incidence is driving a 3.6 fold increase in liver disease in Wales over 21 years. Liver-related morbidity and mortality rose more slowly reflecting the lower progression rate in NAFLD. Incidence of ArLD remained stable but was associated with the highest rates of liver-related and all-cause mortality.
肝病发病率上升,因此对肝病服务的需求也在增加。
描述威尔士肝病的发病率和自然史趋势,为有效提供肝病服务提供依据。
该登记册收录了1999年至2019年间根据死亡率数据以及住院/日间病例活动得出的居民国际疾病分类第十版(ICD-10)编码诊断。通过对以下内容进行伪匿名链接:(1)病因诊断;(2)肝硬化;(3)门静脉高压;(4)失代偿;(5)肝癌诊断,从而能够追踪肝病进展情况。
2019年威尔士人口为310万。1999年至2019年间,有73054人被诊断患有肝病,其中18633人被诊断患有肝硬化,10965人出现肝失代偿,2316人患有肝细胞癌(HCC)。在21年的时间里,肝病发病率增长了3.6倍,主要是由非酒精性脂肪性肝病(NAFLD)发病率增长10倍所驱动;自2014年起,NAFLD成为肝病的主要病因。肝硬化、失代偿、HCC以及全因死亡率均增长了两倍。肝病相关死亡率增长了一倍。酒精性肝病(ArLD)、自身免疫性肝病和充血性肝病与最高的失代偿率和全因死亡率相关。
在21年的时间里,NAFLD发病率增长10倍推动了威尔士肝病发病率增长3.6倍。肝病相关的发病率和死亡率上升较为缓慢,这反映出NAFLD的进展速度较低。ArLD的发病率保持稳定,但与最高的肝病相关死亡率和全因死亡率相关。